Nye krystalformer af Perindopril erbumin

Disclosed are two new crystalline forms, δ and , of perindopril erbumine. Those forms are suitable as therapeutic active substances for medicaments for the treatment of cardiovascular diseases, especially high blood pressure and heart failure. The crystalline form is obtained in the crystallization...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: LELLEK, VIT, FAESSLER, ROGER, STRAESSLER, CHRISTOPH
Format: Patent
Sprache:dan
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator LELLEK, VIT
FAESSLER, ROGER
STRAESSLER, CHRISTOPH
description Disclosed are two new crystalline forms, δ and , of perindopril erbumine. Those forms are suitable as therapeutic active substances for medicaments for the treatment of cardiovascular diseases, especially high blood pressure and heart failure. The crystalline form is obtained in the crystallization of perindopril erbumine at from 30 to 45° C., preferably from 34 to 45° C., from MTBE containing from 1.5 to 2.5% (v/v) water; the crystallization is advantageously carried out with stirring. If the water is then removed, advantageously by azeotropic distillation, preferably at from 35 to 37° C., and stirring is then continued for at least 15 h at from 30 to 45° C., preferably from 35 to 37° C., the crystalline form is converted to the δ crystalline form. The δ crystalline form can also be obtained by stirring the α or crystalline form at from 33 to 38° C. in tert.-butyl methyl ether containing from 0.9 to 1.4% (v/v) water with seeding with the δ crystalline form. The crystalline form can also be obtained by stirring the α or crystalline form at from 28 to 35° C. in tert.-butyl methyl ether containing from 0.9 to 1.4% (v/v) water with seeding with the crystalline form; or by stirring the α or crystalline form at from 35 to 38° C. in tert.-butyl methyl ether containing from 1.5 to 2.0% (v/v) water.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_DK1636185TT3</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>DK1636185TT3</sourcerecordid><originalsourceid>FETCH-epo_espacenet_DK1636185TT33</originalsourceid><addsrcrecordid>eNrjZNDwq0xVyC6qLC5JzEnLL8pNLVJITFMISC3KzEvJLyjKzFFILUoqzc3M42FgTUvMKU7lhdLcDIpuriHOHrqpBfnxqcUFicmpeakl8S7ehmbGZoYWpiEhxsbEqAEA9j8o_Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Nye krystalformer af Perindopril erbumin</title><source>esp@cenet</source><creator>LELLEK, VIT ; FAESSLER, ROGER ; STRAESSLER, CHRISTOPH</creator><creatorcontrib>LELLEK, VIT ; FAESSLER, ROGER ; STRAESSLER, CHRISTOPH</creatorcontrib><description>Disclosed are two new crystalline forms, δ and , of perindopril erbumine. Those forms are suitable as therapeutic active substances for medicaments for the treatment of cardiovascular diseases, especially high blood pressure and heart failure. The crystalline form is obtained in the crystallization of perindopril erbumine at from 30 to 45° C., preferably from 34 to 45° C., from MTBE containing from 1.5 to 2.5% (v/v) water; the crystallization is advantageously carried out with stirring. If the water is then removed, advantageously by azeotropic distillation, preferably at from 35 to 37° C., and stirring is then continued for at least 15 h at from 30 to 45° C., preferably from 35 to 37° C., the crystalline form is converted to the δ crystalline form. The δ crystalline form can also be obtained by stirring the α or crystalline form at from 33 to 38° C. in tert.-butyl methyl ether containing from 0.9 to 1.4% (v/v) water with seeding with the δ crystalline form. The crystalline form can also be obtained by stirring the α or crystalline form at from 28 to 35° C. in tert.-butyl methyl ether containing from 0.9 to 1.4% (v/v) water with seeding with the crystalline form; or by stirring the α or crystalline form at from 35 to 38° C. in tert.-butyl methyl ether containing from 1.5 to 2.0% (v/v) water.</description><language>dan</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; METALLURGY ; ORGANIC CHEMISTRY</subject><creationdate>2012</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20120507&amp;DB=EPODOC&amp;CC=DK&amp;NR=1636185T3$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20120507&amp;DB=EPODOC&amp;CC=DK&amp;NR=1636185T3$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>LELLEK, VIT</creatorcontrib><creatorcontrib>FAESSLER, ROGER</creatorcontrib><creatorcontrib>STRAESSLER, CHRISTOPH</creatorcontrib><title>Nye krystalformer af Perindopril erbumin</title><description>Disclosed are two new crystalline forms, δ and , of perindopril erbumine. Those forms are suitable as therapeutic active substances for medicaments for the treatment of cardiovascular diseases, especially high blood pressure and heart failure. The crystalline form is obtained in the crystallization of perindopril erbumine at from 30 to 45° C., preferably from 34 to 45° C., from MTBE containing from 1.5 to 2.5% (v/v) water; the crystallization is advantageously carried out with stirring. If the water is then removed, advantageously by azeotropic distillation, preferably at from 35 to 37° C., and stirring is then continued for at least 15 h at from 30 to 45° C., preferably from 35 to 37° C., the crystalline form is converted to the δ crystalline form. The δ crystalline form can also be obtained by stirring the α or crystalline form at from 33 to 38° C. in tert.-butyl methyl ether containing from 0.9 to 1.4% (v/v) water with seeding with the δ crystalline form. The crystalline form can also be obtained by stirring the α or crystalline form at from 28 to 35° C. in tert.-butyl methyl ether containing from 0.9 to 1.4% (v/v) water with seeding with the crystalline form; or by stirring the α or crystalline form at from 35 to 38° C. in tert.-butyl methyl ether containing from 1.5 to 2.0% (v/v) water.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2012</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZNDwq0xVyC6qLC5JzEnLL8pNLVJITFMISC3KzEvJLyjKzFFILUoqzc3M42FgTUvMKU7lhdLcDIpuriHOHrqpBfnxqcUFicmpeakl8S7ehmbGZoYWpiEhxsbEqAEA9j8o_Q</recordid><startdate>20120507</startdate><enddate>20120507</enddate><creator>LELLEK, VIT</creator><creator>FAESSLER, ROGER</creator><creator>STRAESSLER, CHRISTOPH</creator><scope>EVB</scope></search><sort><creationdate>20120507</creationdate><title>Nye krystalformer af Perindopril erbumin</title><author>LELLEK, VIT ; FAESSLER, ROGER ; STRAESSLER, CHRISTOPH</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_DK1636185TT33</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>dan</language><creationdate>2012</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><toplevel>online_resources</toplevel><creatorcontrib>LELLEK, VIT</creatorcontrib><creatorcontrib>FAESSLER, ROGER</creatorcontrib><creatorcontrib>STRAESSLER, CHRISTOPH</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>LELLEK, VIT</au><au>FAESSLER, ROGER</au><au>STRAESSLER, CHRISTOPH</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Nye krystalformer af Perindopril erbumin</title><date>2012-05-07</date><risdate>2012</risdate><abstract>Disclosed are two new crystalline forms, δ and , of perindopril erbumine. Those forms are suitable as therapeutic active substances for medicaments for the treatment of cardiovascular diseases, especially high blood pressure and heart failure. The crystalline form is obtained in the crystallization of perindopril erbumine at from 30 to 45° C., preferably from 34 to 45° C., from MTBE containing from 1.5 to 2.5% (v/v) water; the crystallization is advantageously carried out with stirring. If the water is then removed, advantageously by azeotropic distillation, preferably at from 35 to 37° C., and stirring is then continued for at least 15 h at from 30 to 45° C., preferably from 35 to 37° C., the crystalline form is converted to the δ crystalline form. The δ crystalline form can also be obtained by stirring the α or crystalline form at from 33 to 38° C. in tert.-butyl methyl ether containing from 0.9 to 1.4% (v/v) water with seeding with the δ crystalline form. The crystalline form can also be obtained by stirring the α or crystalline form at from 28 to 35° C. in tert.-butyl methyl ether containing from 0.9 to 1.4% (v/v) water with seeding with the crystalline form; or by stirring the α or crystalline form at from 35 to 38° C. in tert.-butyl methyl ether containing from 1.5 to 2.0% (v/v) water.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language dan
recordid cdi_epo_espacenet_DK1636185TT3
source esp@cenet
subjects CHEMISTRY
HETEROCYCLIC COMPOUNDS
METALLURGY
ORGANIC CHEMISTRY
title Nye krystalformer af Perindopril erbumin
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T02%3A45%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=LELLEK,%20VIT&rft.date=2012-05-07&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EDK1636185TT3%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true